Datametrex AI Ltd. (TSX-V: DM, OTC: DTMXF, Forum) announced on Tuesday that submitted a Medical Devices Interim Order Request Form to approve
PCL, Inc.’s COV05 COVID19 Rapid Antigen Detection Kits to Health Canada. The Company stated that it will be able to provide a minimum first order of 200,000, followed by an additional 200,000 units on a weekly basis.
Datametrex CEO Marshall Gunter stated that this test can detect antigens of COVID-19 from a swab in the nose and throat to provide results in 5-10 minutes with over 86% accuracy.
To read more from this report, click
here.
The Canadian tech Company recently reported that its revenue increased by
419% in Q2 compared to the same time last year, earning $2.7 million (CAD) for the six-month 2020 period, compared to $875,000 in same period 2019, of which $1.9 million was earned in Q2. The Company’s cash position rose to $577,998 from $119,675 at the end of 2019.
FULL DISCLOSURE: Datametrex AI Ltd. is a client of Stockhouse Publishing.